ClinicalTrials.gg
RecruitingNCT03954899Updated Sep 28, 2026

Disease Modifying Potential of 5mg of Melatonin on Cognition and Brain Health in Aging

An interventional study of melatonin and placebo in Mild Cognitive Impairment, Cognitive Decline and Healthy Aging, sponsored by Natalie Denburg. Recruiting at 1 site in United States. Open to participants aged 56 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Natalie Denburg · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Started Nov 2019; still recruiting 7 years later.
Updated Sep 28, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
230
Allocation
Randomized
Ages
56 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 1,421 studies in Cognitive Dysfunction with a site in United States — 328 open to participants now, 431 under way, 13 of them phase 3. Cognitive Dysfunction · United States.

Planned enrollment
157th of 1,146
230 · median 59
Started
2019
with 88 others
No phase
715 of 1,421
181 open now
Primary completion
2028-02
later than 304 of 430 live
Registered
659th of 1,421
by date

Among the 1,421 studies in Cognitive Dysfunction with a site in United States, this one is the 157th largest by planned enrollment of the 1,146 interventional ones that give a count, is one of 89 that started in 2019, is one of 715 with no phase, reaches primary completion later than 304 of the 430 other live ones, and was the 659th registered.

Cognitive Dysfunction

3,881 studies on the registry are indexed under Cognitive Dysfunction; 1,121 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

328 of the 1,421 studies in Cognitive Dysfunction with a site in United States are open now. Recruiting first, the newest first:

323 more — sign in →

All 328 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 752 Cognitive Dysfunction studies recruiting now, 362 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 56 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,421 studies in Cognitive Dysfunction with a site in United States, or all of them as a file.
02

Study summary

The study will examine whether 5mg melatonin (over the counter, OTC) over a 9-month period improves Alzheimer's disease (AD) biomarkers and cognitive function in two groups of individuals: those with mild cognitive impairment (MCI+) and those who are not (MCI-). AD biomarkers will be measured from cerebrospinal fluid (CSF) obtained from lumbar punctures. Cognitive function will be evaluated with routine neuropsychological tests.

AS OF AUGUST 2024, THE LUMBAR PUNCTURE PROCEDURES FOR THIS CLINICAL TRIAL HAVE BEEN ELIMINATED. THAT IS, PARTICIPANTS ARE NO LONGER RECEIVING A LUMBER PUNCTURE. BUT ARE CONTINUING TO RECEIVE TWO SEPARATE BLOOD DRAWS FOR BIOMARKER TESTING.

Read the detailed description

To address these broad aims, participants will be recruited from the Neuropsychology Clinic, community, Alzheimer's association local chapter events and support groups, senior citizen centers. Following fulfillment of several inclusionary and exclusionary criteria online/on the phone, participants will first complete a baseline visit with several tests designed to measure aspects of motor, affective, and cognitive function. The baseline visit will be briefer for those who do not fulfill in-person components of the inclusionary/exclusionary criteria (BMI\<35; MoCA>=18; and CDR \<=.5).

Based on the information obtained during the baseline visit, participants' cognitive status will be categorized as either MCI+ or MCI-. The criteria adopted in this study for a determination of MCI is less stringent than typical clinical criteria. This information will be used to conduct stratified randomization of participants to placebo or active (5mg melatonin) arms. The schedule of randomization will be determined by University of Iowa Hospital \& Clinic's pharmacy so that study personnel and participants will not know which participant has been assigned to which study arm.

At the end of the baseline visit, participants will be given actigraphy watches to wear for a period of 8 weeks, a wash-out phase; phase#1. The watches monitor sleep and circadian rhythm in each participant's daily life. At the end of 8 weeks, participants will return to the lab to complete a brief battery of cognitive tests. At the end of the visit, they will be given freshly charged actigraphy watches to take home with them until week-16 as well as the first supply of study issued medications (beginning phase#2 of the study). They will receive a phone call at the beginning of week-9 to complete brief questionnaires regarding sleep quality, mood, and any physical symptoms that may be associated with study-issued medications. At the week-16 visit, the participants will return their actigraphy watches, complete brief cognitive testing, questionnaires on sleep quality, mood, physical symptoms that may be associated with study-issued medications, and complete the first LP and blood draw. They will also be given their supply of study-issued medications for the next 7-month period. They will receive a phone call around week-30 (midway between week-16 and the final study visit of week-44) to inquire about sleep quality, any physical symptoms that may be associated with study-issued medications, and mood. The final study visit will take place on week-44. The visit will be very similar to the baseline visit and will include comprehensive cognitive testing, questionnaires, and an LP. Participants will also receive a phone call the day after each LP to query them about any discomfort they may be experiencing and the adequacy of over-the-counter pain medications in addressing it.

In addition to these procedures, participants will be asked to consent to banking of CSF for assaying of future biomarkers during the two study LPs.

AS OF AUGUST 2024, THE LUMBAR PUNCTURE PROCEDURES FOR THIS CLINICAL TRIAL HAVE BEEN ELIMINATED. THAT IS, PARTICIPANTS ARE NO LONGER RECEIVING A LUMBER PUNCTURE. BUT ARE CONTINUING TO RECEIVE TWO SEPARATE BLOOD DRAWS AT WEEKS 8 AND 44 FOR BIOMARKER TESTING.

03

Conditions studied

  • Mild Cognitive Impairment
  • Cognitive Decline
  • Healthy Aging
04

Who can participate

Ages eligible
56 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  1. between ages of 56-85 years
  2. all participants must score 18 or above on (MoCA);
  3. all participants must have a clinical dementia rating (CDR) Sum of boxes \<1;
  4. need to be willing to undergo CSF LP on two occasions over the course of their participation,
  5. need to be able and willing to stop using any prescription or non-prescription sleep aids (e.g.(e.g. Ambien, Sonata, Lunesta, Belsomra, Rozerem, Halcion, Intermezzo, Doxepin, Melatonin, etc.) for the duration of the study except for study-issued medications
  6. \< 35 at the time of enrollment
  7. willing to bring a study partner (spouse, child or friend) who knows them well to each of the four visits

AS OF AUGUST 2024, THE LUMBAR PUNCTURE PROCEDURES FOR THIS CLINICAL TRIAL HAVE BEEN ELIMINATED. THAT IS, PARTICIPANTS ARE NO LONGER RECEIVING A LUMBER PUNCTURE. BUT ARE CONTINUING TO RECEIVE TWO SEPARATE BLOOD DRAWS FOR BIOMARKER TESTING.

The exclusion criteria are:

  1. Individuals with any of the following conditions/ diseases will be excluded:

    Obstructive sleep apnea (OSA) without CPAP use, , emphysema, major psychiatric disease (bipolar, schizophrenia), history of alcohol/drug abuse, neurodegenerative disease diagnosis (e.g. Parkinson's, Lewy body, ALS, MS), prior history of stroke or traumatic brain injury, have undergone chemotherapy in the past 2 years, have been hospitalized for injury/surgery in the past three-months.

  2. CDR>=1, depression/anxiety (GDS>=9; GAI>=9 ),
  3. Participants who are on any of the following medications will be excluded: Fluvoxamine (Luvox)/ Fluoxetine (Prozac), Nifedipine (a blood pressure medication), all anti-coagulants (e.g. Warfarin, Coumadin, Heparin, , Lovenox, Xarelto, Pradaxa, etc.), anti-seizure drugs (e.g. Acetazolamide, Carbamazepine, Clobazam, Clonazepam, Gabapentin, etc.), muscle relaxants (e.g.Baclofen, Valium/ diazepam, Flexeril, etc.), or narcotic pain relievers (e.g.Codeine, Tramadol, Hydrocodone, Demerol, etc).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
230 participants (estimated)

Study arms

  • Experimental
    MCI+ Melatonin 5mg

    MCI+ individuals receiving 5mg of melatonin-OTC for a period of 9 months

    Dietary Supplement: melatonin

  • Placebo comparator
    MCI+ placebo

    MCI+ individuals receiving placebo for a period of 9 months

    Other: placebo

  • Experimental
    MCI- Melatonin 5mg

    MCI- individuals receiving 5mg of melatonin-OTC for a period of 9 months

    Dietary Supplement: melatonin

  • Placebo comparator
    MCI- placebo

    MCI- individuals receiving placebo for a period of 9 months

    Other: placebo

Interventions

  • Dietary supplementmelatonin

    5mg of melatonin-otc 30 minutes before sleep

  • Otherplacebo

    placebo 30 minutes before sleep

06

What researchers measure

Primary outcomes

  1. Episodic memory

    Composite episodic memory performance scores will be computed based on the following tests: Auditory Verbal Learning Test (AVLT), Free \& Cued Selective Reminding Test (FCSRT), Repeatable Battery for the Assessment of Neuropsychological Status (Story memory) at the week-8, week-16, and week-44 visits. Alternate forms will be used to assess performance in each of these tests across these visits to minimize practice effects. Composite scores at week-16 and week-44 visits will reference the pretreatment group mean and standard deviations to permit the detection of deviation from pre-treatment levels.

    Time frame: Assessed at pre-treatment (week-8), and two post-treatment occasions: week-16 and week-44.

Secondary outcomes

  1. Overall cognitive function

    Composite performance scores will be computed based on the following cognitive tests: AVLT, FCSRT, RBANS-Story, Benton Visual Retention Test (BVRT), Trail Making Test (PartsA\&B), and Controlled Oral Word Association (COWA) at the week-8, week-16, and week-44 visits. Alternate forms will be used to assess performance in each of these tests, when available, across these visits to minimize practice effects. Composite scores at week-16 and week-44 visits will reference the pretreatment group mean and standard deviations to permit the detection of deviation from pre-treatment levels.

    Time frame: Assessed at pre-treatment (week-8), and two post-treatment occasions: week-16 and week-44.

  2. p-tau/Aβ42 ratio

    Cerebrospinal values from lumbar puncture

    Time frame: Assessed at pre-treatment (week-8) and one post-treatment occasion (week-44)

  3. t-tau

    Cerebrospinal values from lumbar puncture

    Time frame: Assessed at pre-treatment (week-8) and one post-treatment occasion (week-44)

  4. Sleep Efficiency

    Daily Sleep efficiency values obtained from actigraphy during the wash-out period (weeks 1 to 8) and sleep efficiency values obtained from actigraphy during week-8 to week-16 when participants are on placebo or the active arm.

    Time frame: Daily from actigraphy in the pre-treatment phase which lasts 8 weeks (phase#1) and daily from actigraphy in the post-treatment phase from week-9 to week-16 (phase#2).

  5. Amplitude (Mesor) of rest-activity rhythm

    The 30-second activity counts from actigraphy watches will be submitted to cosinor curve analyses to permit the extraction of peak amplitude per day in both phases of the study (wash-out pre-treatment from week-1 to week-8 and week-9 to week-16 post treatment, phase#2). These amplitude values will be averaged to characterize typical amplitude for each participant within each study phase.

    Time frame: Daily from actigraphy in the pre-treatment phase which lasts 8 weeks (phase#1) and daily from actigraphy in the post-treatment phase from week-9 to week-16 (phase#2).

  6. Acrophase of rest-activity rhythm

    The 30-second activity counts from actigraphy watches will be submitted to cosinor curve analyses to permit the extraction of the time of day at peak amplitude per day in both phases of the study (wash-out pre-treatment from week-1 to week-8 and week-9 to week-16 post treatment, phase#2). These acrophase values will be averaged to characterize typical timing of peak amplitude for each participant within each study phase.

    Time frame: Daily from actigraphy in the pre-treatment phase which lasts 8 weeks (phase#1) and daily from actigraphy in the post-treatment phase from week-9 to week-16 (phase#2).

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2019 (actual). Primary completion is estimated for Feb 2028, 99 months after the start.

Of 1,452 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 99 months is above that.

Counting every sponsor, half of 1,521 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 28, 2026: primary completion Nov 2025 → Feb 2028 and completion Nov 2025 → Feb 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2019
First posted
May 17, 2019
StartActual
Nov 12, 2019
Primary completionEst.
Feb 2028was Nov 2025
CompletionEst.
Feb 2028was Nov 2025
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Nov 2025→Feb 2028
Sep 28, 2026
Study completion
Nov 2025→Feb 2028
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Primary completion Nov 2025→Feb 2028
    Study completion Nov 2025→Feb 2028
    + 3 other changes: verification date, oversight details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03954899
Lead sponsor
Natalie Denburg
Responsible party
Natalie Denburg (Associate Professor, University of Iowa) — Sponsor-investigator
First posted
May 17, 2019
Start date
Nov 12, 2019
Primary completion
Feb 2028 (estimated)
Completion
Feb 2028 (estimated)
Last update
Sep 28, 2026

Study contacts

Natalie Denburg, Ph.D
Contact
natalie-denburg@uiowa.edu
3193846050
Natalie Denburg, Ph.D.
principal investigator · University of Iowa

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Melatonin

Start the discussion